Stevanato Group Reports Solid Q1 2026 Results with 7% Revenue Growth and Reaffirms Full-Year Guidance

summarizeSummary

Stevanato Group reported a 7% increase in Q1 2026 revenue (10% constant currency) and a 150 basis point improvement in Adjusted EBITDA margin, while reaffirming its full-year 2026 guidance.

check_boxKey Events

• Strong Q1 Revenue Growth

  Total revenue increased 7% year-over-year (10% on a constant currency basis) to €273.6 million, driven by a 13% increase in the Biopharmaceutical and Diagnostic Solutions (BDS) Segment.

• Adjusted EBITDA Margin Expansion

  Adjusted EBITDA increased to €65.5 million, with the Adjusted EBITDA margin improving 150 basis points to 23.9% compared to the prior-year period.

• Adjusted Diluted EPS Increased

  Adjusted diluted earnings per share rose to €0.11 for Q1 2026, up from €0.10 in the same period last year.

• Full-Year Guidance Reaffirmed

  The company maintained its fiscal 2026 guidance, expecting revenue in the range of €1.26 billion to €1.29 billion and adjusted diluted EPS between €0.59 and €0.63.

auto_awesomeAnalysis

Stevanato Group delivered a solid first quarter, demonstrating continued growth in its core Biopharmaceutical and Diagnostic Solutions (BDS) segment, which saw a 16% increase at constant currency. The company's focus on high-value solutions, particularly in biologics and GLP1s, is driving revenue and margin expansion. While the Engineering segment experienced a decline, its profitability improved due to optimization efforts. The reaffirmation of full-year guidance signals management's confidence in achieving its targets despite ongoing significant capital expenditures for new manufacturing facilities, which impacted free cash flow in the quarter. Investors should monitor the continued ramp-up of these new facilities and the company's ability to convert strategic investments into sustained profitability and cash generation.